Myocardial Perfusion Assessment With Multidetector Computed Tomography

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00846079

Enrollment

100

Registered

2009-02-18

Start date

2009-02-28

Completion date

2009-09-30

Last updated

2009-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

coronary artery disease, stress testing

Brief summary

Demonstrate the ability of muti-detector computed tomography to adequately perform stress testing will result in a veritable one-stop shop of non-invasive cardiac imaging that is, the ability to directly visualize heart arteries with high accuracy and to simultaniously determine the hemodynamic significance of any blockages visualized.

Interventions

DEVICERegadenoson (Lexiscan) [muti-detector computed tomography]

Regadenason, typical dosing

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adults \>18 years of age * Adults undergoing myocardial perfusion SPECT imaging * Adults with suspected coronary artery disease

Exclusion criteria

* Age \<18 * Known or suspected renal insufficiency (Creatinine \<1.7 mg/dl) * Allergy to contrast * Inability or contraindication to lexiscan or beta blocker

Design outcomes

Primary

Measure	Time frame
Diagnostic Accuracy (Sensitivity/Specificity/Positive Predictive Value/Negative Predictive Value)	6 months

Secondary

Measure	Time frame
Radiation dosimetry	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026